Miami, FL – 
Alan Jay Weisberg, Chairman and Chief Executive Officer of Progressive Care, commented, “During 2021, we launched an aggressive expansion of our COVID-19 testing service, which contributed to accelerated revenue growth rates. The fourth quarter was particularly strong, as we continued to market our PharmcoRx brand to corporate clients as a one-stop shop for COVID-19 testing and vaccine management solutions. We believe our positioning as a leading Florida health services organization and provider of COVID-19 testing and vaccine services will build additional value for our shareholders.”
Progressive Care currently operates over 40 COVID-19 Rapid PCR Test analyzers. The Company has built strong relationships with its corporate clients and successfully scaled its infrastructure capable of testing up to 1,000 patients a day, with results in as little as 15 minutes.
Progressive Care provides COVID-19 testing services using the FDA’s Emergency Use Authorization (“EUA”) guidelines, featuring Polymerase Chain Reaction (“PCR”) and Antigen testing systems that produce rapid detection of the SARS-CoV-2 virus, and Antibody testing to detect the presence of IGG and IGM antibodies in the blood.
The systems the Company uses for Rapid Detection of the SARS-CoV-2 virus is a molecular test using a lab technique called PCR, an antigen-based testing system designed to detect proteins from the virus that causes COVID-19, and COVID-19 IgG/IgM Rapid Test Cassette authorized for the detection of antibodies to SARS-CoV-2 in human venous whole blood.
Progressive Care testing sites are equipped with analyzers capable of detecting positive or negative COVID-19 results within minutes. Each Site is operated by clinically trained Pharmacy staff and administering tests on and off site. The Company has established a reputation as a reliable testing partner and currently provides testing services to international travelers and international airlines, chain restaurants, U.S. and international production and entertainment companies, and local healthcare communities. The Company has been able to build an Ecosystem that allows a patient, employer, or coordinator in-charge to chat with the Company’s support team, schedule a test, pay for the test, and at the point of arrival to the site create a profile and access test results by simply scanning a QR code from a mobile device. Using the same Ecosystem, the Company’s support staff can manage the entire patient’s journey and provide automated reporting of the results to regulatory authorities, supervisors and coordinators in-charge.
Progressive Care, Inc.
Progressive Care, Inc. (OTCQB: RXMD), through its subsidiaries, is a Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.
For more information about Progressive Care, please visit the company’s website.
Connect and stay in touch with us on social media:
Progressive Care Inc.
https://www.progressivecareus.com/
https://twitter.com/ProgressCareUS
PharmCoRx
ClearMetrX
https://www.facebook.com/clearmetrx/
Forward-Looking Statements:
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
Public Relations Contact:
Carlos Rangel
carlosr@pharmcorx.com
Investor Relations Contact:
Brian Loper
ClearThink
bloper@clearthink.capital